Effects of Resveratrol Supplementation in Nrf2 and NF-κB Expressions in Nondialyzed Chronic Kidney Disease Patients: A Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Trial

Juliana F. Saldanha; Viviane O. Leal; Felipe Rizzetto; Gustavo H. Grimmer; Marcelo Ribeiro-Alves; Julio B. Daleprane; José C. Carraro-Eduardo; Denise Mafra

doi:10.1053/j.jrn.2016.06.005

Effects of Resveratrol Supplementation in Nrf2 and NF-κB Expressions in Nondialyzed Chronic Kidney Disease Patients: A Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Trial

Journal of Renal Nutrition ◽

10.1053/j.jrn.2016.06.005 ◽

2016 ◽

Vol 26 (6) ◽

pp. 401-406 ◽

Cited By ~ 22

Author(s):

Juliana F. Saldanha ◽

Viviane O. Leal ◽

Felipe Rizzetto ◽

Gustavo H. Grimmer ◽

Marcelo Ribeiro-Alves ◽

...

Keyword(s):

Clinical Trial ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III–IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial

Trials ◽

10.1186/s13063-019-3563-5 ◽

2019 ◽

Vol 20 (1) ◽

Cited By ~ 1

Author(s):

Jing Gan ◽

Yansheng Wu ◽

Xuezhong Gong ◽

Yiyi Ma ◽

Shengqiang Yu ◽

...

Keyword(s):

Clinical Trial ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Autosomal Dominant ◽

Polycystic Kidney ◽

Double Blind ◽

Double Blind Placebo ◽

Autosomal Dominant Polycystic Kidney ◽

Disease Study ◽

Disease Stages

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of an Omega-3 Fatty Acid Supplement in Patients With Predialysis Chronic Kidney Disease

Journal of Renal Nutrition ◽

10.1053/j.jrn.2020.04.004 ◽

2021 ◽

Vol 31 (1) ◽

pp. 64-72

Author(s):

Daniel Bunout ◽

Gladys Barrera ◽

Sandra Hirsch ◽

Eduardo Lorca

Keyword(s):

Clinical Trial ◽

Chronic Kidney Disease ◽

Fatty Acid ◽

Kidney Disease ◽

Controlled Clinical Trial ◽

Omega 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Omega 3 Fatty Acid ◽

Fatty Acid Supplement

Download Full-text

Faculty Opinions recommendation of High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954671.793466054 ◽

2012 ◽

Author(s):

John Eisman

Keyword(s):

Chronic Kidney Disease ◽

Parathyroid Hormone ◽

Kidney Disease ◽

Controlled Trial ◽

High Dose ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735542506.793559665 ◽

2019 ◽

Author(s):

Carmine Zoccali ◽

Davide Bolignano

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Glycaemic Control ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Lowering Effect

Download Full-text

FP413EFFECT OF VITAMIN D SUPPLEMENTATION ON VASCULAR FUNCTION, ENDOTHELIAL AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfv177.12 ◽

2015 ◽

Vol 30 (suppl_3) ◽

pp. iii205-iii208

Author(s):

Ashok Kumar Yadav ◽

Vivek Kumar ◽

Vinod Kumar ◽

Manphool Singhal ◽

Anupam Lal ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Vitamin D ◽

Kidney Disease ◽

Vascular Function ◽

Controlled Trial ◽

Vitamin D Supplementation ◽

Inflammatory Biomarkers ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

FP008ACHIEVEMENT OF NORMAL SERUM POTASSIUM WITH SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) IN A SUBGROUP OF PATIENTS WITH STAGE 4/5 CHRONIC KIDNEY DISEASE AND BASELINE POTASSIUM ≥5.5 MMOL/L FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HARMONIZE STUDY

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfv165.08 ◽

2015 ◽

Vol 30 (suppl_3) ◽

pp. iii68-iii68

Author(s):

Simon D. Roger ◽

Angel de Francisco ◽

Henrik Rasmussen ◽

Philip Lavin ◽

Bhupinder Singh ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Serum Potassium ◽

Normal Serum ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Sodium Zirconium ◽

Stage 4 ◽

Sodium Zirconium Cyclosilicate

Download Full-text

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(19)32135-x ◽

2019 ◽

Vol 394 (10208) ◽

pp. 1540-1550 ◽

Cited By ~ 44

Author(s):

Rajiv Agarwal ◽

Patrick Rossignol ◽

Alain Romero ◽

Dahlia Garza ◽

Martha R Mayo ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Resistant Hypertension ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease—the ASSUAGE-CKD trial

The International Journal of Cardiovascular Imaging ◽

10.1007/s10554-012-0166-6 ◽

2012 ◽

Vol 29 (5) ◽

pp. 1029-1037 ◽

Cited By ~ 22

Author(s):

Rami Doukky ◽

Maria Octavia Rangel ◽

Rizcallah Dick ◽

Marwan Wassouf ◽

Ammar Alqaid ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Myocardial Perfusion Imaging ◽

Kidney Disease ◽

Myocardial Perfusion ◽

Perfusion Imaging ◽

Controlled Study ◽

Side Effect Profile ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Chronic Kidney Disease

Download Full-text

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(13)70208-0 ◽

2014 ◽

Vol 2 (5) ◽

pp. 369-384 ◽

Cited By ~ 308

Author(s):

Anthony H Barnett ◽

Ambrish Mithal ◽

Jenny Manassie ◽

Russell Jones ◽

Henning Rattunde ◽

...

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

Advances in Therapy ◽

10.1007/s12325-019-00943-4 ◽

2019 ◽

Vol 36 (6) ◽

pp. 1438-1454 ◽

Cited By ~ 17

Author(s):

Tadao Akizawa ◽

Manabu Iwasaki ◽

Tetsuro Otsuka ◽

Michael Reusch ◽

Toshihiro Misumi

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Japanese Patients ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text